Esta traducción se está preparando. Mientras tanto, mostramos temporalmente la versión original en inglés.
Negocios · 29/10/19981 min de lectura
Eli Lilly & Co. and Bristol-Myers Squibb Co.; Withdrawal of Approval of Three New Drug Applications for Estrogen-Androgen Combination Drugs
Traducción automática local · Idioma original de la fuente
Resumen
The Food and Drug Administration (FDA) is withdrawing approval of three new drug applications (NDA's) for estrogen-androgen combination drugs. The NDA's are held by Eli Lilly & Co. and Bristol- Myers Squibb Co. The products are no longer marketed. Both companies requested that the NDA's be withdrawn and waived their opportunity for a hearing. The products will be removed from the list of drug products with effective approvals.
Idioma original de la fuente: Federal Register — Food and Drug AdministrationAbrir el comunicado original →